" class="no-js "lang="en-US"> Halia Therapeutics Appoints Former Amgen Executive as CMO
Friday, February 03, 2023

Halia Therapeutics Appoints Former Amgen Executive, Margit M. Janát-Amsbury, MD, Ph.D., as Chief Medical Officer

Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the appointment of Margit Janát-Amsbury, as the company’s Chief Medical Officer (CMO).

Dr. Janát-Amsbury is an experienced leader of cross-functional early development teams in oncology. With 20+ years of experience in academic and industry settings, she has guided numerous oncology assets through Phase 1/2 development and has extensive experience in translational research focused on drug delivery and disease modeling.

“We are delighted to welcome Dr. Janát-Amsbury to our team. Her significant expertise in successfully driving clinical development of oncology drug candidates will prove invaluable to the company as we continue to advance the development of our lead compound, HT-6184, for treating diseases driven by chronic inflammation,” said Dr. David J. Bearss, President and Chief Executive Officer of Halia Therapeutics.

“I am honored to join Halia Therapeutics and work alongside this accomplished multi-disciplinary team of scientists and innovators. The company’s unique approach of targeting the NLRP3 inflammasome to resolve chronic inflammation has enormous potential within multiple therapeutic areas. I look forward to contributing to the company’s mission and developing Halia’s pipeline. ” said Dr. Margit M. Janát-Amsbury, Halia Therapeutics, CMO.

Prior to joining Halia Therapeutics as Chief Medical Officer, Dr. Janát-Amsbury served as an Executive Medical Director in Early Oncology Development at Amgen and was also the Product Team Lead for Amgen’s prostate portfolio. Before joining Amgen, she oversaw the development of multiple small molecules at Tolero Pharmaceuticals, which Sumitomo Dainippon Pharma acquired in 2017. Dr. Janát-Amsbury has held faculty appointments with the Division of Gynecologic Oncology, the Department of Pharmaceutics and Pharmaceutical Chemistry, as well as the Department of Bioengineering at the University of Utah, where she also served as Co-Director of the Center for Nanomedicine. Dr. Janát-Amsbury received her MD and Ph.D. from the Albertus Magnus University in Cologne, Germany.

  1. Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Read more
  2. Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Read more
  3. Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Read more
  4. Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Read more
  5. Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest Read more